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Rationale and Methodology
• For this initial testing phase only the fibrinogen beta gene (FBG) is being 
expressed
• This gene was selected due to the availability of  an expression plasmid in E. Coli
for propagation and cultivation of  the matured protein
• FBG processes antimicrobial properties
• Propagating E. Coli bacteria transformed with FBG containing plasmid
• Extraction of  FBG containing plasmid
• Preparation of  liposomes for transfection (lipofection)
• Transfecting (lipofecting) plasmid into mammalian cell line
• Propagating mammalian cells, which was selected as Mus musculus (mouse cells)
• Expressing FBG
• Extraction and purification of  mature FBG using Ni-NTA affinity resin
• Characterization of  FBG via Bradford assay for protein concentration 
measurements and SDS-PAGE and Western blot or turbidity measures when the 
protein is incubated with thrombin
Future Work
• Propagate and extract the plasmids from the E. Coli cultures
• Transfect them into the mammalian cell line through the use of a liposome
to transfect the cells
• Cultivate cells
• Extract mature Fibrinogen B-Chain and purify
• Evaluate for concentration and function
• Next, would be to work on incorporating all three genes into one plasmid or
series of plasmids to incorporate them into one cell to produce fully formed
fibrinogen protein
• The final step would be to modify the gene sequence to create different
forms of fibrinogen to explore the impact on the formation of fibrin
matrices to study in models of wound healing
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Introduction
Wounding healing is broken down into four phases: Hemostasis, Inflammation,
Proliferation, and Remodeling. A detailed explanation can be seen in Figure 1.
Once wounded, fibrinogen is then recruited to the site during the hemostasis phase,
where it is then cleaved by thrombin to form a fibrin matrix that it is replaced with
collagen.
The structure of fibrinogen is composed of two sets of three chains: alpha, beta,
and gamma chains. See Figure 2. The alpha chain is primarily involved in forming
the matrix, the beta chain in addition to helping form the matrix it possesses
antimicrobial properties, and the gamma chain helps with stabilizing the matrix
and adhering to the fibroblast cells.
Disorders associated with fibrinogen are presented in Figure 3 and primarily come
in two forms: Fibrinogenemia (low or absent levels of fibrinogen) and
Dysfibrinogenemia (normal levels of fibrinogen but lacks proper function). Both of
these are often treated with fibrinogen concentrates or factor replacements to help





• After the E. Coli are sufficiently grown and the plasmid lipofected into the 
mouse cells, large amounts should be produced as a majority of  fibrinogen is 
typically produced in the liver cells
• We hope that after we obtain Fibrinogen B-Chain, we can form some form 
of  fibrin gel when it is introduced to thrombin and any other clotting factors, 
such as Factor XIII.  Figure 5 shows a fibrin gel
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Discussion
• For this study, two cells types are being used: E. Coli (as mentioned earlier)
and Mus musculus (mouse) liver cells
• Fibrinogen is produced mainly within the liver cells of the body. By using
liver tissue, we expect to be able to provide the provide the protein with all
the necessary components to fold and be modified properly
• As of now, after extensive preliminary research and sourcing of the
necessary materials, we have begun by propagating the plasmid containing
bacteria
• However, due to the recent global pandemic, further work has been greatly
slowed
Figure 1: The Phases of  Wound Healing [1]
Figure 2: Structure of  Fibrinogen [3]
Figure 5: Fibrin Gel [4]
Figure 3: Types of  Fibrinogen Disorders [2]
Plasmid 
Propagation
• Growing cells on plates w/ LB Broth and Ampicillin




• Breaking down the E. Coli cells to release plasmids
• Separation of  plasmids from the rest of  the cellular content
• Lipofecting the new cells with the plasmids
Fibrinogen 
Production
• Using T-90 flasks, the cells are then plated and grown
• After a growth period, Fibrinogen is then extracted and purified
Figure 4: Steps for Fibrinogen B-Chain Production
Introduction (cont.)
The primary purpose of this study is to develop the materials and protocols necessary
to enable production of “clean” and functional samples of fibrinogen in the lab for
wound healing studies. A main challenge is to transfer the genes to express the
fibrinogen chains in either bacterial cells or mammalian cells. Bacterial cells are less
expensive to maintain in the lab and can potentially grow faster, but they typically do
not modify proteins after translation the same way that animal cells do, a set of steps
that is crucial for fibrinogen’s function. Mammalian cells can form the correct structure
with the appropriate post-translational modifications necessary but are far more
expensive to culture and maintain in the lab.
